HomeCompareMGYOY vs JNJ

MGYOY vs JNJ: Dividend Comparison 2026

MGYOY yields 6.22% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MGYOY wins by $21841.50M in total portfolio value
10 years
MGYOY
MGYOY
● Live price
6.22%
Share price
$6.01
Annual div
$0.37
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21841.53M
Annual income
$21,187,077,579.47
Full MGYOY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — MGYOY vs JNJ

📍 MGYOY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMGYOYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MGYOY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MGYOY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MGYOY
Annual income on $10K today (after 15% tax)
$528.63/yr
After 10yr DRIP, annual income (after tax)
$18,009,015,942.55/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, MGYOY beats the other by $18,009,011,956.56/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MGYOY + JNJ for your $10,000?

MGYOY: 50%JNJ: 50%
100% JNJ50/50100% MGYOY
Portfolio after 10yr
$10920.78M
Annual income
$10,593,541,134.43/yr
Blended yield
97.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

MGYOY
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
2.5
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MGYOY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMGYOYJNJ
Forward yield6.22%2.13%
Annual dividend / share$0.37$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%28%
Portfolio after 10y$21841.53M$30.3K
Annual income after 10y$21,187,077,579.47$4,689.40
Total dividends collected$21796.28M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: MGYOY vs JNJ ($10,000, DRIP)

YearMGYOY PortfolioMGYOY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,944$1,243.83$10,592$272.30+$1.4KMGYOY
2$15,557$2,776.83$11,289$357.73+$4.3KMGYOY
3$23,406$6,760.37$12,123$472.89+$11.3KMGYOY
4$44,056$19,011.97$13,141$629.86+$30.9KMGYOY
5$114,029$66,888.97$14,408$846.81+$99.6KMGYOY
6$445,611$323,599.50$16,021$1,151.60+$429.6KMGYOY
7$2,840,508$2,363,704.19$18,122$1,588.22+$2.82MMGYOY
8$31,202,381$28,163,037.45$20,930$2,228.20+$31.18MMGYOY
9$611,638,945$578,252,397.81$24,792$3,191.91+$611.61MMGYOY
10$21,841,531,251$21,187,077,579.47$30,274$4,689.40+$21841.50MMGYOY

MGYOY vs JNJ: Complete Analysis 2026

MGYOYStock

MOL Magyar Olaj- és Gázipari Nyilvánosan Muködo Részvénytársaság, together with its subsidiaries, operates as an integrated oil and gas company in Hungary and internationally. It operates through five segments: Upstream, Downstream, Consumer Services, Gas Midstream, and Corporate and Other. The company is involved in the refining, transportation, and storage of crude oil; wholesale and retail of crude oil products; geothermal energy production; natural gas transmission; feed water and raw water supply; water transportation; refinery and marketing of oil and petrochemical products; importing and exporting of energetical products; warehousing and oil product storage activities; and exploration and production of crude oil, natural gas, and other gas products. It also engages in the provision of transportation, fleet management, and financial services; marketing agency activities; production and distribution of electricity; production and retail trade of lubricants; and retail and wholesale trade of fuels. In addition, the company provides business, accounting, IT, and company services; construction and engineering, pipeline construction, and leasing activities; repair and maintenance services; investment management services; and real estate management services, as well as manufactures and sells machinery and equipment. Further, it engages in the mineral water production and distribution activities; exploration of hydrocarbon; provision of exploration financing, car sharing, firefighting, tourism, oilfield, and rental services; petrochemicals and consumer retail activities, as well as provision of fire, hospitality, and catering services; and operation of café houses. The company was incorporated in 1991 and is headquartered in Budapest, Hungary.

Full MGYOY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this MGYOY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MGYOY vs SCHDMGYOY vs JEPIMGYOY vs OMGYOY vs KOMGYOY vs MAINMGYOY vs ABBVMGYOY vs MRKMGYOY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.